KRISTINE MOLLOHAN: Open Payments
NPI 1801213301 · SHEFFIELD, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$631 in 38 payments from 11 companies in 2025. Trend: 2023 $943 · 2024 $638 · 2025 $631
Food & beverage: $631
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $170 |
| Vanda Pharmaceuticals Inc. | 4 | $118 |
| AstraZeneca Pharmaceuticals LP | 4 | $103 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| PFIZER INC. | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Alkermes, Inc. | 1 | $28 |
| Amgen Inc. | 2 | $28 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $25 |
Products named: FANAPT, FARXIGA, VRAYLAR, UBRELVY, QULIPTA, RECORLEV, CAPLYTA, VIVITROL.
Industry payments across AL — which companies pay providers there.
